Loading
If this is the first time anyone has visited this substance, we may be fetching live data from TGA Product Information, PBS, and state framework sources — that can take up to a minute. Cached substances load in a second or two.
Ranibizumab, sold under the brand name Lucentis among others, is a monoclonal antibody fragment (Fab) created from the same parent mouse antibody as bevacizumab. It is an anti-angiogenic that is approved to treat the "wet" type of age-related macular degeneration (AMD, also ARMD), diabetic retinopathy, and macular edema due to branch retinal vein occlusion or central retinal vein occlusion.
Read the full article on WikipediaSubfoveal choroidal neovascularisation (CNV) Clinical criteria: Treatment Phase: Initial treatment Treatment criteria: Must be treated by an ophthalmologist or by an accredited ophthalmology registrar in consultation with an ophthalmologist. The condition must be due to age-related macular degeneration (AMD), AND The condition must be diagnosed by optical coherence tomography; OR The condition must be diagnosed by fluorescein angiography, AND The treatment must be the sole PBS-subsidised therapy for this condition. Authority approval for initial treatment of each eye must be sought. The first authority application for each eye must be made via the Online PBS Authorities System (real time assessment) or in writing via HPOS form upload or mail and must include: (1) Details (date, unique identifying number/code or provider number) of the optical coherence tomography or fluorescein angiogram report. If the application is submitted through HPOS form upload or mail, it must include: (a) details of the proposed prescription; and (b) a completed authority application form relevant to the indication and treatment phase (the latest version is located on the website specified in the Administrative Advice). All reports must be documented in the patient's medical records.
Proliferative diabetic retinopathy (PDR) and/or Diabetic macular oedema (DMO) Clinical criteria: Treatment Phase: Initial treatment Patient must have documented visual impairment defined as a best corrected visual acuity score between 78 and 39 letters based on the early treatment diabetic retinopathy study chart administered at a distance of 4 metres (approximate Snellen equivalent 20/32 to 20/160), in the eye proposed for treatment. This is only a requirement for patients being treated for DMO, AND The condition must be diagnosed by an ophthalmologist or by an accredited ophthalmology registrar in consultation with an ophthalmologist, AND The condition must be diagnosed by optical coherence tomography; OR The condition must be diagnosed by fluorescein angiography; OR The condition must be diagnosed by retinal photography, AND The treatment must be the sole PBS-subsidised therapy for this condition, AND The treatment must be as monotherapy; OR The treatment must be in combination with laser photocoagulation, AND Patient must not have previously received PBS-subsidised treatment with this drug for this indication for the same eye. Treatment criteria: Must be treated by an ophthalmologist or by an accredited ophthalmology registrar in consultation with an ophthalmologist. Authority approval for initial treatment of each eye must be sought. Details (date, unique identifying number/code or provider number) of one of the following diagnostic reports for each eye must be documented in the patient's medical records: (i) fluorescein angiogram report; (ii) optical coherence tomography report; (iii) retinal photography report.
Branch retinal vein occlusion with macular oedema Clinical criteria: Treatment Phase: Initial treatment Treatment criteria: Must be treated by an ophthalmologist or by an accredited ophthalmology registrar in consultation with an ophthalmologist. Patient must have visual impairment due to macular oedema secondary to branched retinal vein occlusion (BRVO), AND Patient must have documented visual impairment defined as a best corrected visual acuity score between 73 and 20 letters based on the early treatment diabetic retinopathy study chart administered at a distance of 4 metres (approximate Snellen equivalent 20/40 to 20/400), in the eye proposed for treatment, AND The condition must be diagnosed by optical coherence tomography; OR The condition must be diagnosed by fluorescein angiography, AND The treatment must be the sole PBS-subsidised therapy for this condition. Authority approval for initial treatment of each eye must be sought. The first authority application for each eye must be made via the Online PBS Authorities System (real time assessment) or in writing via HPOS form upload or mail and must include: (1) Details (date, unique identifying number/code or provider number) of the optical coherence tomography or fluorescein angiogram report. If the application is submitted through HPOS form upload or mail, it must include: (a) details of the proposed prescription; and (b) a completed authority application form relevant to the indication and treatment phase (the latest version is located on the website specified in the Administrative Advice). All reports must be documented in the patient's medical records.
Central retinal vein occlusion with macular oedema Clinical criteria: Treatment Phase: Initial treatment Treatment criteria: Must be treated by an ophthalmologist or by an accredited ophthalmology registrar in consultation with an ophthalmologist. Patient must have visual impairment due to macular oedema secondary to central retinal vein occlusion (CRVO), AND Patient must have documented visual impairment defined as a best corrected visual acuity score between 73 and 24 letters based on the early treatment diabetic retinopathy study chart administered at a distance of 4 metres (approximate Snellen equivalent 20/40 to 20/320), in the eye proposed for treatment, AND The condition must be diagnosed by optical coherence tomography; OR The condition must be diagnosed by fluorescein angiography, AND The treatment must be the sole PBS-subsidised therapy for this condition. Authority approval for initial treatment of each eye must be sought. The first authority application for each eye must be made via the Online PBS Authorities System (real time assessment) or in writing via HPOS form upload or mail and must include: (1) Details (date, unique identifying number/code or provider number) of the optical coherence tomography or fluorescein angiogram report. If the application is submitted through HPOS form upload or mail, it must include: (a) details of the proposed prescription; and (b) a completed authority application form relevant to the indication and treatment phase (the latest version is located on the website specified in the Administrative Advice). All reports must be documented in the patient's medical records.
“Approx. 9 days”
Working under the parallel aged-care framework? Aged-care equivalent →